Associated Papers
A New Cloud-Native Tool for Pharmacogenetic Analysis.
Yuan DY et al.
Genes, 2024
Synergy of Mutation-Induced Effects in Human Vitamin K Epoxide Reductase: Perspectives and Challenges for Allo-Network Modulator Design.
Botnari M et al.
International Journal of Molecular Sciences, 2024
Missense VKOR mutants exhibit severe warfarin resistance but lack VKCFD via shifting to an aberrantly reduced state.
Li S et al.
Blood Advances, 2023
Multiplexed measurement of variant abundance and activity reveals VKOR topology, active site and human variant impact.
Chiasson MA et al.
Elife, 2020
Stabilization of warfarin-binding pocket of VKORC1 and VKORL1 by a peripheral region determines their different sensitivity to warfarin inhibition.
Shen G et al.
Journal of Thrombosis and Haemostasis : Jth, 2018
Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting.
Kalman LV et al.
Clinical Pharmacology and Therapeutics, 2016
Characterization of 137 Genomic DNA Reference Materials for 28 Pharmacogenetic Genes: A GeT-RM Collaborative Project.
Pratt VM et al.
The Journal of Molecular Diagnostics : Jmd, 2016
A Novel Admixture-Based Pharmacogenetic Approach to Refine Warfarin Dosing in Caribbean Hispanics.
Duconge J et al.
Plos One, 2016
[Resistance to acenocoumarol revealing a missense mutation of the vitamin K epoxyde reductase VKORC1: a case report].
Mboup MC et al.
Annales De Cardiologie Et D'angeiologie, 2015
Identification of VKORC1 genotype leading to resistance to tecarfarin.
Matagrin B et al.
Journal of Clinical Pharmacology, 2014
A Proposal for an Individualized Pharmacogenetic-Guided Warfarin Dosage Regimen for Puerto Rican Patients Commencing Anticoagulation Therapy.
Bosch LA
Journal of Pharmacogenomics & Pharmacoproteomics, 2014
Pharmacogenetics in Jewish populations.
Yang Y et al.
Drug Metabolism and Drug Interactions, 2014
Warfarin pharmacogenetics: a controlled dose-response study in healthy subjects.
Kadian-Dodov DL et al.
Vascular Medicine (london, England), 2013
VKORC1 mutations detected in patients resistant to vitamin K antagonists are not all associated with a resistant VKOR activity.
Hodroge A et al.
Journal of Thrombosis and Haemostasis : Jth, 2012
Prediction of warfarin dose reductions in Puerto Rican patients, based on combinatorial CYP2C9 and VKORC1 genotypes.
Valentin II et al.
The Annals of Pharmacotherapy, 2012
Pharmacogenetics, pharmacogenomics, and individualized medicine.
Ma Q et al.
Pharmacological Reviews, 2011
Thirteen novel VKORC1 mutations associated with oral anticoagulant resistance: insights into improved patient diagnosis and treatment.
Watzka M et al.
Journal of Thrombosis and Haemostasis : Jth, 2011
Exposure to non-therapeutic INR in a high risk cardiovascular patient: potential hazard reduction with genotype-guided warfarin (Coumadin) dosing.
Rodríguez-Vélez R et al.
Puerto Rico Health Sciences Journal, 2010
CYP2C9 and VKORC1 genotypes in Puerto Ricans: A case for admixture-matching in clinical pharmacogenetic studies.
Villagra D et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry, 2010
Comparison of assay systems for warfarin-related CYP2C9 and VKORC1 genotyping.
Maurice CB et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry, 2010
Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population.
Lubitz SA et al.
Journal of Thrombosis and Haemostasis : Jth, 2010
[The pharmacogenetics of vitamin K antagonists: still a matter for discussion].
Moreau C et al.
La Revue De Medecine Interne, 2010
CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing.
Scott SA et al.
Pharmacogenomics, 2009
Prevalence of combinatorial CYP2C9 and VKORC1 genotypes in Puerto Ricans: implications for warfarin management in Hispanics.
Duconge J et al.
Ethnicity & Disease, 2009
Pharmacodynamic resistance to warfarin is associated with nucleotide substitutions in VKORC1.
Harrington DJ et al.
Journal of Thrombosis and Haemostasis : Jth, 2008
Oral anticoagulants: Pharmacogenetics Relationship between genetic and non-genetic factors.
D'Andrea G et al.
Blood Reviews, 2008
Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations.
Scott SA et al.
American Journal of Human Genetics, 2008
Building individualized medicine: prevention of adverse reactions to warfarin therapy.
Krynetskiy E et al.
The Journal of Pharmacology and Experimental Therapeutics, 2007
Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes.
Zhu Y et al.
Clinical Chemistry, 2007
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.
Rieder MJ et al.
The New England Journal of Medicine, 2005